Daily Stock List
Rich Pharmaceuticals, Inc. (RCHA)
Greenbackers reported recently on Rich Pharmaceuticals, Inc. (RCHA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Rich Pharmaceuticals, Inc. is a Biopharmaceutical Company whose shares trade on the OTC Bulletin Board. The Company is developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. It is concentrating on the development of its lead product, RP-323 (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The Company’s objective is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals has its corporate headquarters in Beverly Hills, California.
The design of its’ RP-323 is to treat blood and cancer related diseases by way of none evasive outpatient facilities. On the whole, Rich is focusing on the discovery, development, and commercialization of drugs to treat unmet medical needs in oncology that function at the DNA level. The Company’s mission is to develop these small-molecule compounds to treat cancer and stroke in patients with the greatest unmet medical needs.
Recently, Rich Pharmaceuticals announced that it entered into an agreement with Richard L. Chang Holdings, LLC, headquartered in New Jersey, for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin's Lymphoma. Hodgkin lymphoma is a cancer of the immune system, which is marked by the presence of a type of cell called the Reed-Sternberg cell. At present, this disease affects more than 100,000 patients each year.
With this agreement, Rich Pharmaceuticals will obtain complete ownership and all interest in the indication, patents, as well as intellectual property (IP) related to treatment of Hodgkin's Lymphoma, utility patent application number 61998397, entitled Compositions And Methods Of Use Of Phorbol Esters For The Treatment Of Hodgkin's Lymphoma.
In addition, Rich Pharmaceuticals recently announced that it submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). The Company’s intention is to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients.
Rich Pharmaceuticals, Inc. (RCHA), closed Friday's trading session at $0.00805, down 19.50%, on 1,411,632 volume with 35 trades. The average volume for the last 60 days is 574,885 and the stock's 52-week low/high is $0.007/$0.455.
eRoomSystem Technologies, Inc. (ERMS)
Today we choose to report on eRoomSystem Technologies, Inc. (ERMS), here at the QualityStocks Daily Newsletter.
eRoomSystem Technologies, Inc. is a leader in fully-automated computerized refreshment centers (mini-bar), safes, and other integrated in-room technologies. The Company’s products are installed in top hotel chains and independent lodging properties globally. In January 2014, eRoomSystem Technologies introduced to the lodging industry an amenity management platform, or the Amenities Manager. The intention of the Amenities Manager is to help hotels decrease their operating costs and enhance the hotels' guest satisfaction. This would eventually enable hotels to charge more for their rooms and services.
eRoomSystem Technologies designs in-room systems, markets, services and finances its products to meet its customers' exact requirements. The aforementioned amenity management platform’s core is proprietary, unique software, which provides a locally hosted or cloud-based system intended to assist a hotel in evaluating the gross profit margin of different refreshment center products, determining which products will best sell in the hotel's particular environment, and determining which products are consistent with and could enrich the hotel's image and theme.
eRoomSystem Technologies’ intention is that its hotel customers will eventually share in revenues produced from the sale of products from the Company’s refreshment centers related to its platform. As an alternative solution, the Company additionally plans to offer a turnkey arrangement where it would provide products and restocking services to hotels.
The Company currently generates revenues from the sale of products in hotel in-room refreshment centers, from maintenance services, as well as the lease of equipment. For the three months ended September 30, 2014 and 2013 revenue from product sales and maintenance was $198,051 for the three months ended September 30, 2014, versus $145,239 for the three months ended September 30, 2013. This represents an increase of $52,812, or 36 percent. The increase in revenues was related to new hotels coming on board in the last part of 2013 and in 2014.
eRoomSystem Technologies achieved net income of $9,329 for the three months ended September 30, 2014. This is in comparison to a net loss of $56,989 for the three months ended September 30, 2013.
eRoomSystem Technologies, Inc. (ERMS), closed Friday's trading session at $0.07, even for the day. The average volume for the last 60 days is 24,588 and the stock's 52-week low/high is $0.045/$0.13.
Kips Bay Medical, Inc. (KIPS)
Equity Observer, Value Penny Stocks, Ascending Stocks, HotStockProfits, StockLockandLoad, StockBomb.com, ResearchOTC, StockRockandRoll, and PennyStockLocks.com reported on Kips Bay Medical, Inc. (KIPS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Kips Bay Medical, Inc. is a medical device company with corporate headquarters in Minneapolis, Minnesota. The Company concentrates on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting (CABG surgery). Kips Bay Medical was formed in 2007 by Mr. Manuel (Manny) A. Villafaña (Chairman and CEO of Kips Bay Medical). Mr. Villafaña has 50-plus years of experience in the medical device industry.
The Company originally acquired the eSVS Mesh® technology from Medtronic, Inc. in 2007. Kips Bay Medical lists on the OTCQB Marketplace. Its common stock commenced trading on the OTCQB on September 12, 2014.
The Company’s product is built on the proprietary eMesh technology platform. The intention of it is to provide improved outcomes for patients suffering with coronary artery disease who require CABG surgery. The design of the Kips Bay Medical eSVS Mesh is to address the limitations of saphenous vein grafts (SVGs) used in CABG surgery. The eSVS Mesh is fitted like a sleeve on the outside of saphenous vein grafts to strengthen SVGs used in CABG surgery.
In addition, the innovative design is intended to ensure that blood flow is faster and more laminar, through reducing the diameter mis-match between the SVG and target artery. The eSVS Mesh is manufactured from nitinol wire. This gives the eSVS Mesh substantial strength, while remaining highly flexible and kink-resistant.
Kips Bay Medical’s commitment is to performing clinical studies to demonstrate long-term outcome results for the eSVS Mesh technology. Presently, the Company is involved in a Food and Drug Administration (FDA)-mandated feasibility study and is sponsoring continuing post-market studies in Europe. Kips Bay Medical has received an updated CE Mark approving use of a new surgical implant technique for its eSVS Mesh.
Last month, Kips Bay Medical Chairman and CEO, Manny Villafana, announced that on November 4, 2014, cardiac surgeons at The Valley Hospital's Heart and Vascular Institute in Ridgewood, New Jersey, performed their first implant of an eSVS Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial now taking place for the U.S. Food and Drug Administration (FDA) in several preeminent cardiac surgery centers in Europe and the U.S.
Kips Bay Medical, Inc. (KIPS), closed Friday's trading session at $0.155, up 14.73%, on 36,634 volume with 13 trades. The average volume for the last 60 days is 66,589 and the stock's 52-week low/high is $0.1253/$0.334.
Sanomedics International Holdings, Inc. (SIMH)
Wall Street Resources, PennyStockRumors.net, and PricelessPennyStocks reported recently on Sanomedics International Holdings, Inc. (SIMH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Miami, Florida-based Sanomedics International Holdings, Inc. is a medical technology holding Company. It centers on game-changing products, services, and ideas, and physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and eventually commercialization. The Company’s goal is to act as a bridge between the high-technology medical world and the home healthcare environment.
Sanomedics manufactures and distributes unique professional medical and home health diagnostic devices and products. It announced in September of 2013 that it completed the acquisition of Prime Time Medical, Inc., of Largo, Florida. Prime Time Medical is a leading Durable Medical Equipment (DME) provider of home medical equipment.
The design of all Sanomedics professional and home healthcare diagnostic products are to be user-friendly. This is while providing a high degree of health benefits and accurate results. Sanomedics’ plan is to grow its existing business organically and through strategic acquisitions specifically relating to sleep disorder diagnosis treatments. It looks to acquire sleep therapy service operating businesses that can undergo integration into its operations. Moreover, it will look for acquisition and development opportunities related to other aspects of the sleep disorder marketplace.
Sanomedics’ strategy is to integrate a portfolio of world-class products and service providers in the growing Sleep Apnea market. Its aim is to provide Sleep Apnea patients with a reliable and integrated "end-to-end" service platform.
Sanomedics’ new subsidiary, SanoER LLC, signed a Letter of Intent (LOI) to acquire a freestanding 5,000 sq. ft., state of the art emergency room. This facility will be the first in Sanomedics’ overall strategy to become a major operator of Free Standing Emergency Rooms in this market. SanoER specializes in the development, management and acquisition of Freestanding Emergency Rooms (FSER).
Sanomedics’ Thermomedics subsidiary has strengthened its position in the Professional Healthcare vital signs business with the signing of a long-term agreement with Novation (Irving, Texas), a world-renowned provider of healthcare supply chain expertise and contracting. The three-year agreement went into effect on October 1, 2014. Thermomedics designs, develops and markets medical diagnostic equipment for professional healthcare providers.
In November, Sanomedics International Holdings announced its financial results for Q3 2014. Highlights include revenue increasing 33 percent year over year; gross profit increased 85 percent year over year, and the Company’s backlog continues to increase.
Sanomedics International Holdings, Inc. (SIMH), closed Friday's trading session at $0.009, down 10.00%, on 3,598,456 volume with 97 trades. The average volume for the last 60 days is 6,889,006 and the stock's 52-week low/high is $0.009/$4.75.
FluoroPharma Medical, Inc. (FPMI)
TaglichBrothers and Streetwise Reports reported earlier on FluoroPharma Medical, Inc. (FPMI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
FluoroPharma Medical, Inc. specializes in the development of novel diagnostic imaging products, which utilize Positron Emission Tomography (PET) technology for the detection and assessment of disease before clinical manifestation. The Company is a biopharmaceutical entity engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. FluoroPharma Medical has licensed technology from the Massachusetts General Hospital in Boston, Massachusetts. The Company has its corporate headquarters in Montclair, New Jersey.
Patents related to FluoroPharma Medical’s portfolio of imaging compounds have been issued in the United States, Europe, China, Japan, Canada, Australia, and Mexico. FluoroPharma’s initial focus is the development of innovative PET imaging agents. It is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease.
The design of these first in class agents is to target, fast, myocardial cells. Other products in development include agents for the detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease, and agents that could potentially be used for imaging specific cancers.
CardioPET™ is one of FluoroPharma's first in class PET imaging products. CardioPET™ is a perfusion and fatty acid uptake indicator. The design of it is for use as a cardiac imaging agent. It may be a more specific alternative to currently available diagnostic tests. FluoroPharma Management believes its pharmacokinetic characteristics could be especially valuable in patients who are unable to exercise.
In addition, FluoroPharma has its BFPET PET Scan Imaging Agent. BFPET is a Flourine-18 labeled tracer. The design of it is to enter the myocardial cells in direct proportion to blood flow and cell membrane potential.
FluoroPharma also has its VasoPET. Through targeting the active adenosine phosphate molecule receptors associated with inflammatory conditions, the VasoPET imaging agent allows FluoroPharma to visualize potential areas that may cause embolisms and thrombosis. The Company also has its AZPET PET Scan Imaging Agent. AZPET attaches to the amyloid deposits (plaque) in the brain and makes them visible on a PET Scan. As a result, this allows for the early detection of Alzheimer's disease.
Yesterday, FluoroPharma Medical announced scheduled completion of enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD). It announced that enrollment for this Phase II trial will be closing on December 15, 2014. So far, FluoroPharma believes it has obtained sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.
FluoroPharma Medical, Inc. (FPMI), closed Friday's trading session at $0.475, up 14.46%, on 114,167 volume with 48 trades. The average volume for the last 60 days is 31,468 and the stock's 52-week low/high is $0.3272/$0.92.
Breitling Energy Corp. (BECC)
BUYINS.NET reported earlier on Breitling Energy Corp. (BECC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2004, Breitling Energy Corp. is an oil and gas exploration and production company listed on the OTC Markets’ OTCQB. It acquires and develops lower risk onshore oil and gas working interests (WIs) and royalty interests in proven basins in the U.S. Bering Exploration, Inc. announced on January 22, 2014, that it changed its name to Breitling Energy Corp. Breitling Energy is based in Dallas, Texas.
Breitling Energy’s oil and gas operations are centered primarily in the Permian Basin of Texas and the Mississippi oil window of southern Kansas and Northern Oklahoma. The Company has non-operating investments in Texas, North Dakota, Oklahoma, and Mississippi. Its operating areas are represented by long-lived natural gas and oil reserves and established production capabilities with plentiful growth opportunities.
Breitling Energy announced in September 2014 that the second well under its Farmout Agreement in Sterling County Texas reached an approximate total depth of 9,000 feet. The Hoppe '63' #1 was spudded September 12, 2014. Breitling reported that the well encountered the same productive formations as in its initial Sterling County well, the Parramore #1. Breitling’s intention is to drill eight wells on its Sterling County property to earn the total acreage under the Farmout Agreement.
The Company’s Buresh 17-#1HM well in Sumner County, Kansas went online on September 11, 2014, producing around 127 barrels of oil and a significant amount of flowback water during the first 12 hours. The well's oil production has continued to grow.
Breitling Energy reported this past October that it continues to move ahead with the upcoming completion of its second Permian Basin well (Hoppe "63" #1 in Sterling County, Texas). The well reached a total depth of roughly 8,600 ft. in the Lower Strawn on September 24, 2014. It was logged on the following day. Physical hydrocarbon shows and oil indicators on the logs were present in many formations.
This week, Breitling Energy announced the formation of its Asset Management division as a revenue center and a risk diversification strategy. The Asset Management division consists of two sub-divisions. One is Portfolio Management and the other is Oil and Gas Management. The Portfolio Management sub-division manages portfolios of royalty and non-operated working interests. The design of the Oil and Gas Management sub-division is to help Breitling minimize risk through divesting a portion of each of its wells via strategic industry relationships.
Yesterday, Breitling Energy announced that its Chief Executive Officer, Chris Faulkner, was recognized this week by the Dallas Business Journal Who’s Who in Energy, 2014. The recognition includes seven energy markets across the United States, and in addition to Dallas, includes Columbus, Denver, Houston, Pittsburgh, San Antonio and St. Louis.
Breitling Energy Corp. (BECC), closed Friday's trading session at $0.52, up 1.96%, on 94,685 volume with 53 trades. The average volume for the last 60 days is 49,857 and the stock's 52-week low/high is $0.0617/$0.95.
Innovus Pharmaceuticals, Inc. (INNV)
StockMister, Penny Stock Circle, StockMarketQuote.us, 1-2-3 Stock Alerts, Fortune Stock Alerts, and OTPicks reported recently on Innovus Pharmaceuticals, Inc. (INNV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Innovus Pharmaceuticals, Inc. is an emerging pharmaceuticals company headquartered in San Diego, California. It delivers non-prescription over-the counter (OTC) medicine and consumer care products to improve men and women's health and vitality. The Company markets its products in the United States and Canada via retailers and on the web. In addition, Innovus details its products to urologists, gynecologists and sex therapists. It does so either directly in the United States or through commercial partners around the world. Innovus Pharmaceuticals lists on OTC Markets’ OTCQB.
Its current product portfolio consists of Zestra® (for female arousal, desire and satisfaction), EjectDelay™ (for premature ejaculation), Sensum+™ (for reduced penile sensitivity - for sales outside the U.S. only), Zestra Glide® (a high viscosity low molarity female water based lubricant) and Vesele®. Vesele® is a proprietary, novel, and safer oral dietary supplement to maximize nitric oxide's beneficial effects on sexual function and brain health. Vesele® contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®.
Innovus Pharmaceuticals earlier announced the availability of its OTC benzocaine-based topical premature ejaculation treatment EjectDelay™ in the U.S. The product is available in two sizes in the U.S., as a 2 ounce tube and as a 5ml single use packet. The EjectDelay™ product license has been approved in Canada.
This past September, Innovus Pharmaceuticals announced that it entered into an exclusive marketing and distribution agreement with Tramorgan Limited, a British company. Innovus has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus’ topical consumer care product to increase penile sensitivity, Sensum+™, in the United Kingdom.
The agreement has an initial term of December 31, 2016. It can be extended for a 24 month period if Tramorgan has reached certain aggregate sales milestones. The product will be available in 10ml multi-dose dispenser and single use packets.
Last week, Innovus Pharmaceuticals announced a positive analysis and outcome of a 246 use survey study in the United Kingdom for Zestra® in women, conducted by Semprae Laboratories before its acquisition by Innovus Pharma, but never reported. In this use survey study, 246 women, including a considerable number of nurse practitioners between the ages of 30-60 years old, used Zestra® over a two-week period. Innovus announced a 77 percent achievement of increase in arousal from the 246 use survey study in British women that used Zestra®.
Innovus Pharmaceuticals, Inc. (INNV), closed Friday's trading session at $0.18, up 4.65%, on 16,555 volume with 3 trades. The average volume for the last 60 days is 28,582 and the stock's 52-week low/high is $0.1105/$0.93.
Cleartronic, Inc. (CLRI)
The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.08, up 60.00%, on 1,332 volume with 2 trades. The stock’s average daily volume over the past 60 days is 5,933, and its 52-week low/high is $0.04/$0.5499.
Consorteum Holdings, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.
VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.
A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.
Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer
Cleartronic, Inc. Company Blog
Cleartronic, Inc. News:
Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors
Cleartronic Announces License Agreement With Collabria LLC
Cleartronic, Inc. (CLRI) Developing 'Capitalization Benefit Plan'
IFAN Financial, Inc. (IFAN)
The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.62, up 12.93%, on 1,418,413 volume with 564 trades. The stock’s average daily volume over the past 60 days is 286,308, and its 52-week low/high is $0.0114/$0.62.
IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.
Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.
Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.
IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer
IFAN Financial, Inc. Company Blog
IFAN Financial, Inc. News:
IFAN Financial, Inc. (IFAN) CEO Featured in Exclusive QualityStocks Interview
IFAN Financial, Inc. (IFAN) Announces Engagement of QualityStocks Investor Relations Services
IFAN Financial Acquires Mobile Payment Solutions Provider Mobicash America, Inc.
Pan Global Corp. (PGLO)
The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.0143, up 13.49%, on 177,943 volume with 18 trades. The stock’s average daily volume over the past 60 days is 91,644, and its 52-week low/high is $0.005/$0.385.
Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer
Pan Global Corp. Company Blog
Pan Global Corp. News:
Pan Global, Corp. Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017
Pan Global, Corp. Shareholder Update: Small-Hydro Plant Connected to Power Grid in Northern India
Pan Global, Corp. Increases Equity Stake in 5.7 MW Small-Hydro Plant in Northern India
Ecrypt Technologies, Inc. (ECRY)
The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.425, up 8.14%, on 4,447,916 volume with 1,286 trades. The stock’s average daily volume over the past 60 days is 1,222,506 and its 52-week low/high is $0.09/$0.508.
Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.
Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.
The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.
Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer
Ecrypt Technologies, Inc. Blog
Ecrypt Technologies, Inc. News:
Microsoft CSO and Ecrypt CEO Share Inaugural Security Industry Award
Ecrypt's Market Alliance Member, Cicada Security Technology Inc., Announces the Launch of New Data Privacy Products
Ecrypt Technologies Secures Multi-Year Contract With Global High Tech Manufacturer
Nhale, Inc. (NHLE)
The QualityStocks Daily Newsletter would like to spotlight Nhale, Inc. (NHLE). Today, Nhale, Inc. closed trading at $0.58, up 3.57%, on 72,004 volume with 53 trades. The stock’s average daily volume over the past 60 days is 39,780, and its 52-week low/high is $0.14/$1.33.
Nhale, Inc. (NHLE) develops and sells leading-edge technology in alignment with its mission to become a recognized, premier innovator in cannabis cultivation, dispensaries, testing and scientific products. Nhale explores innovations that will position the company on the front lines of the marijuana revolution.
Nhale is currently aggressively focused on grow operations in states where cannabis is legal, or soon to be legal, such as Oregon, Alaska and Florida. As an increasing number of states move towards legalization for medical or recreational use, growers are positioned to benefit from economies of scale due to escalating demand. Focusing on candidates in the cultivation space, Nhale is poised grow into a successful, sustainable enterprise through product or company acquisition in this explosive space.
Growpod, Nhale’s self-contained grow environment technology, is one of the company’s products and an entry point into the promising cultivation technology space. Growpod uses “controlled environment agriculture” to optimize plant development, plant quality and production efficiency in all climates and seasons.
Nhale believes innovation produces profitability, especially in growth-stage organizations entering emerging industries. This belief guides Nhale’s strong commitment to develop and commercialize cutting-edge consumer-oriented products primed for rapid commercialization. The company has identified strategic industry partnerships to support this growth objective and to secure an increasing footprint in the booming marijuana market. Disclaimer
Nhale, Inc. Company Blog
Nhale, Inc. News:
Nhale (NHLE) Working to Secure $10 Million in Financing
Marijuana Grow and Retail Operation Taps Nhale (NHLE) for Collaboration
Nhale (NHLE) Considers Acquisitions in Washington as Pot Acreage on Pace to Quadruple
Mobile Lads Corp. (MOBO)
The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.2499, even for the day, on 20,650 volume with 5 trades. The stock’s average daily volume over the past 60 days is 45,173, and its 52-week low/high is $0.1201/$0.42.
Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.
xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.
xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.
The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.
Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer
Mobile Lads Corp. Company Blog
Mobile Lads Corp. News:
Mobile Lads Acquires Innovative Online Coupon Platform, CouBox
Mobile Lads Signs Reseller Agreement With Smart Mobile Rewards
Mobile Lads Signs Letter of Intent for Xtreme Mobility Software Acquisition
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.004, even with yesterday's close. The stock’s average daily volume over the past 60 days is 44,121, and its 52-week low/high is $0.0031/$0.019.
Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.
Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.
Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Signs License Agreement With NYG Holdings
Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited
Consorteum Holdings Launches New Mobile Results App for Popular Keno Game
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Boreal Water Collection, Inc. (BRWC) to Exhibit at China's Largest Food Show
- Cannabics Pharmaceuticals, Inc. (CNBX) Signs IP Licensing and Collaboration Agreement in Spain
- Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Appoints International Business Professional to Board of Directors
- Ecrypt Technologies, Inc. (ECRY) Microsoft CSO and Ecrypt CEO Share Inaugural Security Industry Award
- Falcon Crest Energy (FCEN) Names Michael Cvetanovic to Advisory Council
- IFAN Financial, Inc. (IFAN) CEO Featured in Exclusive QualityStocks Interview
- Intercept Energy Services, Inc. (IESCF) Reports Third Quarter 2014 Results and Engages Investor Relations Firm
- Mobile Lads Corp. (MOBO) Acquires Innovative Online Coupon Platform, CouBox
- Nhale, Inc. (NHLE) Working to Secure $10 Million in Financing
- One World Holdings, Inc. (OWOO) The One World Doll Project Announces First Order From Walmart
- Pan Global Corp. (PGLO) Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017
- Pure Hospitality Solutions, Inc. (OTHMD) 3rd Quarter Filing Shows Promise of Increased Positive Value: Revenue and Hard Assets Prove True
- Sibling Group Holdings, Inc. (SIBE) Blended Schools Network Partners With BloomBoard, Inc. for Teacher Professional Development
- Technology Applications International, Inc. (NUUU) Rejuvel Int'l, Inc. Will Have its Products Included in Celebrity Gift Bags at the 15th Annual Latin GRAMMY® Awards Show at the MGM Grand in Las Vegas
- VistaGen Therapeutics, Inc. (VSTA) Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) to host second webinar on proprietory micro-refinery technology
- WordLogic Corp. (WLGC) the Sale of Exclusive Rights to Legal Enterprise Solutions to Private Equity Group
- WRIT Media Group, Inc. (WRIT) Announces Product Updates and NASCAR Event Recap
- Zenosense, Inc. (ZENO) Stock Now DTC DWAC/FAST Eligible